Abstract
Over the past decades, the incidence and modality of invasive fungal infections have been significantly underestimated. And the limited availability of clinically effective antifungals further underscores the need for novel therapeutic agents. In this study, a series of novel 8-hydroxyquinolin-5-ylidene thiosemicarbazone derivatives (A5-A32) were designed and synthesized via a condensation reaction between 5-formyl-8-hydroxyquinoline and substituted hydrazinecarbothioamides. The in vitro antifungal activity of all synthesized compounds was evaluated against a panel of clinically relevant fungal pathogens using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method, with minimum inhibitory concentrations (MICs) ranging from 4 to ≤ 0.0313 μg/mL. Notably, compound A14 was the most active, demonstrating the lowest MICs among the compounds against each of the tested seven fungal pathogens. Specifically, A14 exhibited remarkable potency against Cryptococcus gattii, C. neoformans, C. glabrata, and C. auris, with MICs ranging from ≤ 0.0313 to 2 μg/mL. This potency is significantly higher than that of the lead compound 5r (MICs: 0.25- >16 μg/mL) and fluconazole (MICs: 2->16 μg/mL). Furthermore, A14 inhibited hyphal formation in C. albicans SC5314 at 8 μg/mL, and remarkably inhibited biofilm formation in both C. albicans SC5314 and C. neoformans H99, achieving >90 % suppression at 32 μg/mL. The cytotoxic effects of compound A14 on the viability of HUVECs and Caco-2 cells were evaluated using the CCK-8 assay, demonstrating acceptable safety profiles. As an innovative antifungal agent, 8-hydroxyquinolin-5-ylidene thiosemicarbazone A14 warrants further investigation.